Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01664091 · ClinicalTrials.gov registry record · NA
Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT01664091 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 32 participants.
The verdict
NCT01664091, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
This research study is being done to carefully evaluate the effect of giving radiation therapy after temporary breast reconstruction. The investigators want to see if this type of reconstruction combined with radiation will look better (once the final reconstruction has been completed) and will reduce the risk that the participant will develop complications that sometimes occur with other kinds of reconstruction procedures. The investigators also want to know if it is easier to give the radiation with this type of reconstruction than with other kinds of reconstruction procedures. The reconstruction procedure involves the temporary use of a tissue expander and an acellular dermal matrix (ADM).
Interventions
- RADIATION post-mastectomy radiation therapy (PMRT)
- DEVICE tissue expander (TE)
- DEVICE acellular dermal matrix (ADM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01664091
The ClinicalTrials.gov registry entry for NCT01664091 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which post-mastectomy radiation therapy (PMRT) is the first listed.
NCT01664091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01664091 about?
NCT01664091 is a clinical study titled "Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT". This research study is being done to carefully evaluate the effect of giving radiation therapy after temporary breast reconstruction. The investigators want to see if this type of reconstruction combined with radiation will look better (once the final reconstruction has been completed) and will redu...
What is the current status of trial NCT01664091?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2009-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01664091?
The interventions under investigation include: post-mastectomy radiation therapy (PMRT) (RADIATION), tissue expander (TE) (DEVICE), acellular dermal matrix (ADM) (DEVICE).
Who is sponsoring clinical trial NCT01664091?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.